Abstract: A cosmetic ink composition comprises a particulate material, a polymeric dispersant, a rheology modifier, and a surface tension modifier, wherein the surface tension modifier is selected from the group consisting of C1-C16 alcohols, C5-C18 diols, and mixtures thereof. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a surface tension of from about 20 to about 45 mN/m.

Abstract: A cosmetic ink composition comprises a particulate material, a polymeric dispersant, a rheology modifier, and a surface tension modifier, wherein the surface tension modifier is selected from the group consisting of C1-C16 alcohols, C5-C18 diols, and mixtures thereof. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a surface tension of from about 20 to about 45 mN/m.

Abstract: A method to quickly adjust the size of micelles and then return the micelles to a persistent state is provided. Specifically, the present invention is directed to a method for block copolymer micelle growth under high-?N solution conditions where ultrasonic cavitation facilitates rapid solution-gas interface production that accelerates micelle growth by an order of magnitude over other methods such as vortexing. The persistent micelles formed by the method of the present invention can then be used for controlled delivery of dispersions in organic electronic coatings, paint, or drug delivery applications and can also be used to control the pore size of films that include an oxide, a nitride, a carbide, a metal, or a carbon material.

Abstract: Implantable materials visible under ultrasound may delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.

Abstract: The present invention is directed to a liposomal formulation comprising a lipid ingredient encapsulating vilanterol trifenatate, and a method for administering the liposomal formulation by nebulizing the liposomal formulation in an inhaler. The liposomal formulation comprises vilanterol or a salt thereof, and lipid ingredients comprising a pharmaceutical lipid and/or a sterol. The drug to lipid mass ratio is in the range of about 1:20 to about 1:100. Additionally, the present invention is directed to the use of the liposomal formulation for the prevention or treatment of respiratory diseases such as Chronic Obstructive Pulmonary Disease and/or asthma.

Abstract: Methods of using the alpha-2-adrenergic receptor agonist of Formula I: for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.

Abstract: Disclosed herein are methods of making pure chalcogenide (e.g., selenium, tellurium, or selenium/tellurium) nanoparticles by irradiating chalcogenide pellets by nano-second laser ablation using chitosan as a capping agent to form chitosan chalcogenide nanoparticles (CS-CgNPs). CS-CgNPs and methods of using such particles are also disclosed herein, such as antimicrobials and antimicrobial coatings effective against biofilms.

Abstract: The invention provides methods for the preparation of particles including one or more agents, e.g., therapeutic or diagnostic agents. The particles can be formed by creating droplets of a first liquid, e.g., including an agent, and removing the first liquid, e.g., through its dispersal in a second liquid and/or evaporation, to solidify the droplets. Advantageously, the process of forming the particles does not significantly alter the structure or activity of the agents and may enhance the stability of the agents. For example, the particles may be stored for long periods of time without significant loss of activity, and in some embodiments, without the need for refrigeration. These particles may be used to generate stabilized pharmaceutical compositions for storage or other logistical purposes, pharmaceutical suspensions, pharmaceutical powder formulations (e.g., inhalable powders, injectable powders), creams or other topical pastes, nutraceuticals, or cosmetics.

Abstract: The disclosure provides, methods for preparing scavenging particles, as well as methods for attaching capture agents to the particles. The disclosure further provides compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. The compositions may comprise a plurality of particles that specifically bind a target, such as a soluble biomolecule or a biomolecule on the surface of a pathogen, to inhibit the target (or pathogen) from interacting with other molecules or cells. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Abstract: A process for forming microspheres is disclosed. The process includes contacting a solvent with a modified cellulose to form a solution; contacting the modified cellulose solution with at least one bioactive agent to form a discontinuous phase liquid; contacting the discontinuous phase liquid with a continuous phase liquid to form an emulsion; and contacting the emulsion with a third phase liquid to extract the solvent from the emulsion, thereby forming a plurality of modified cellulose microspheres.

Abstract: A combination comprising, spatially separate from one another, a first component and a second component, where the first component comprises crosslinkable albumin and the second component comprises a polymer, wherein non-terminal monomer units of the polymer comprise at least partially, more particularly only partially, an albumin-crosslinking group. Additionally disclosed is a reaction product obtainable by means of the combination, to a medical device, to a medicinal product for innovative therapies, to a kit, to a discharge apparatus, and to a functionalized hyaluronic acid.

Abstract: Provided are nutritional supplements designed for enhancing the growth, particularly the linear growth, of pre-pubertal children with a stature measure short compared to the norm. The nutritional composition comprises an energy source, and a combination of micronutrients, and is adapted separately for the nutritional needs of male or female adolescents.

Abstract: This invention discloses methods and composition to form biodegradable polymer implant arrays in the live tissue. Artificial cavities are created in the live tissue by using laser ablation, oscillating needle, microneedle array and other methods. The cavities are then filled with biodegradable polymer solution. The solvent in the polymer solution is dissipated in the tissue to form a biodegradable polymer implant in artificial cavities. The cavities and implants formed are arranged to form of an array of implants. The biodegradable polymer in the cavity can also be loaded with drug to form biodegradable drug delivery array in the live tissue.

Abstract: There may be provided compositions of lipophilic pharmaceutical agents with improved solubility and stability. For example, there may be provided a non-aqueous composition that comprises a lipophilic pharmaceutical agent, and an amphiphilic polymeric solvent such as PEG400 but essentially free of organic solvents and non-solubilized particles. The composition may be further diluted with a desired aqueous diluent such as an infusion fluid for parenteral administration to a subject such as a human. The compositions may be useful for the treatment for diseases or conditions that are sensitive to lipophilic agents, such as infectious diseases, malignant or autoimmune diseases.

Abstract: Articles can be provided with odor resistance by applying a dispersion of a halogenated heterocyclic N-halamine in an inert liquid carrier onto the surface of the article and allowing the inert liquid carrier to penetrate into it. The N-halamine accordingly becomes deposited on the surface of the article after the inert liquid carrier penetrates into the article. This method can be used to provide odor resistance to a variety of substrates, including garbage bags. It can also be used to deposit other functional particulates onto the surface of substrates having sufficient porosity to take up the vehicle. For instance, such functional particles can be oxidants that display antimicrobial and/or enzyme inhibitory efficacy or particles having toxin interaction potentials through oxidative degradation or adsorption of toxic substances in air and/or water, such as fluoride uptake by metal oxide microparticles.

Abstract: A deodorant stick having a substituted or unsubstituted 2-pyridinol-N-oxide material and at least one material selected from the group consisting of hexamidine, magnesium carbonate, zinc carbonate, thymol, magnesium hydroxide, dead sea salt, calcium carbonate, polyvinyl formate, salycilic acid, niacinamide, and combinations thereof.

Abstract: Provided is an external skin preparation capable of enhancing permeability of an active ingredient into parts of the epidermis located below the stratum corneum and the dermis even when a poorly water-soluble active ingredient is used. There is provided an external skin preparation containing a core-shell structure, comprising a core portion containing a poorly water-soluble active ingredient and a solubilizing agent, and a shell portion containing a surfactant. The solubilizing agent is at least one selected from the group consisting of cyclodextrin, methyl-cyclodextrin, dimethyl-cyclodextrin, 2-hydroxypropyl-cyclodextrin, hydroxyethyl-cyclodextrin, sulfobutyl ether-cyclodextrin, glucosyl-cyclodextrin, maltosyl-cyclodextrin and cluster dextrin. The surfactant is at least one selected from the group consisting of glycerol fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and fatty acid alkanolamides.

Abstract: The sterilizing and deodorizing agents target bacteria, odors, toxic substances, etc. and are made from silver as metal particles and titanium dioxide as ceramic particles by (1) thermal bonding or (2) pressure bonding or (3) thermal/pressure bonding and mixing the resultant with hydroxyapatite as an adsorptive material. The agent can be mixed with ink, bonding agents and paints and applied to a variety of substrates.

Abstract: A pressed biomass component is disclosed. The pressed biomass component includes plant or animal material that is compressed by a press plate apparatus by application of pressure within a range of 1000 to 36000 pounds per square inch (PSI). The pressed biomass component is a resultant of the application of the pressure to the plant or animal material and typically has a weight of 0.5-10 grams. The pressed biomass component of claim 1 may be formed in a disc shape including a curved perimeter, a top surface and a bottom surface oriented in parallel with the top surface; thus, resembling a coin. The application of pressure to the press plate apparatus forms the pressed biomass component to support a desired burn time when placed on a heating apparatus. The heating apparatus often includes a ceramic bulb having a wattage within a wattage range of 50 w-150 w.

Abstract: Methods of forming antimicrobial biopolymers from sodium alginate and algae extract using aminoglycosides are presented. Also presented are improved biopolymers, methods of making the biopolymers, and methods of using the biopolymers, wherein the biopolymer includes a sodium alginate and an aminoglycoside.